326 A MULTICENTRE, INTERNATIONAL, DOUBLE BLIND, RANDOMIZED, PLACEBO – CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF 2 DIFFERENT REGIMENS OF HYADD4-G IN KNEE OSTEOARTHRITIS

were no statistically significant group differences for any of the secondary patient-reported outcomes at week 68. Conclusions: A significant weight reduction improves the knee OA patients’ symptoms, as a high proportion of patients experience an OMERACT-OARSI response at 16 weeks. However, although the sustainability of weight loss was significantly better in the diet group, this trial did not provide any evidence of a difference between continuous attention from a dietician following a 1-year maintenance program compared to either exercise or ‘nothing’ in terms of treating OA symptoms.